Forward Pharma is a NASDAQ traded biotechnology company, founded in 2005 in Copenhagen, Denmark. The company is focused on the immunomodulatory compound dimethyl fumarate for the treatment of immune diseases.
FP187 (dimethyl fumarate) is Forward Pharma’s oral fumaric acid ester (FAE) clinical product candidate Read more for treatment of possible immune disorders including multiple sclerosis Read more and psoriasis Read more.
Forward Pharma Reports Fourth Quarter and Year End 2014 Financial and Operational Results
Forward Pharma CFO to Present at the Future Leaders Conference on March 20th
Forward Pharma CFO to Present at Two Upcoming Conferences in February
Forward Pharma Receives Issue Notification for Erosion Matrix Patent in the U.S.
Forward Pharma Sues Biogen Idec over Tecfidera® Sales in Germany
Forward Pharma Exercices Partial Over Allotment Option
Forward Pharma CFO to Present at Two Upcoming Conferences
Forward Pharma A/S Prices Initial Public Offering of ADSs
Forward Pharma files registration statement for IPO on Nasdaq, New York Monday 11. August 2014.
Joel Sendek joins Forward Pharma as Chief Financial Officer.
Forward Pharma Announces Appointment of Dr. Jan G. J. van de Winkel to Board of Directors
Science of dimethyl fumarate
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes. Fox RJ, Mult Scler. 2013. Link
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS. Methner A., Zipp F., Nature Reviews Neurology 2013. Link
Dimethyl Fumarate Modulation of Immune and Antioxidant Responses: Application to HIV Therapy. Gill AJ and Kolson DL, Crit Rev Immunol. 2013. Link
Dimethyl fumarate – only an anti-psoriatic medication? Meissner M et al., JDDG 2012. Link
Dimethyl Fumarate Inhibits Dendritic Cell Maturation via NF-kB and ERK1/2 and MSK1 Signaling. Peng H et al., JBC 2012. Link